Emily M. Leproust Sells 1,726 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 1,726 shares of the business’s stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $41.68, for a total transaction of $71,939.68. Following the completion of the transaction, the chief executive officer now owns 660,966 shares in the company, valued at $27,549,062.88. The trade was a 0.26 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Twist Bioscience Price Performance

Shares of TWST opened at $44.25 on Wednesday. Twist Bioscience Co. has a fifty-two week low of $27.41 and a fifty-two week high of $60.90. The firm’s 50-day simple moving average is $45.45 and its two-hundred day simple moving average is $45.36. The stock has a market cap of $2.64 billion, a PE ratio of -13.09 and a beta of 2.15. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The company had revenue of $88.70 million for the quarter, compared to the consensus estimate of $86.96 million. During the same quarter in the prior year, the business posted ($0.75) EPS. The firm’s quarterly revenue was up 24.1% compared to the same quarter last year. Analysts anticipate that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Analyst Ratings Changes

TWST has been the subject of a number of recent analyst reports. Wolfe Research started coverage on Twist Bioscience in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 price target for the company. Barclays set a $58.00 price target on Twist Bioscience and gave the stock an “overweight” rating in a research note on Monday, February 3rd. Robert W. Baird boosted their price objective on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a research report on Tuesday, February 4th. JPMorgan Chase & Co. raised their target price on shares of Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a research report on Tuesday, February 4th. Finally, TD Cowen reiterated a “buy” rating and set a $58.00 price target on shares of Twist Bioscience in a research report on Tuesday, November 26th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, Twist Bioscience has a consensus rating of “Moderate Buy” and a consensus price target of $54.40.

Hedge Funds Weigh In On Twist Bioscience

A number of hedge funds have recently bought and sold shares of TWST. Van ECK Associates Corp increased its stake in Twist Bioscience by 56.4% during the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock valued at $34,000 after purchasing an additional 267 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of Twist Bioscience during the third quarter valued at approximately $34,000. Banque Transatlantique SA purchased a new position in Twist Bioscience in the 4th quarter worth approximately $43,000. GF Fund Management CO. LTD. bought a new position in Twist Bioscience in the 4th quarter valued at approximately $58,000. Finally, US Bancorp DE boosted its stake in Twist Bioscience by 72.0% during the 4th quarter. US Bancorp DE now owns 1,436 shares of the company’s stock valued at $67,000 after purchasing an additional 601 shares during the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.